| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014 | 2939 | 2014 |
| Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer R Hu, TA Dunn, S Wei, S Isharwal, RW Veltri, E Humphreys, M Han, ... Cancer research 69 (1), 16-22, 2009 | 1330 | 2009 |
| α-Methylacyl-CoA racemase: a new molecular marker for prostate cancer J Luo, S Zha, WR Gage, TA Dunn, JL Hicks, CJ Bennett, CM Ewing, ... Cancer research 62 (8), 2220-2226, 2002 | 832 | 2002 |
| Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer W Liu, S Laitinen, S Khan, M Vihinen, J Kowalski, G Yu, L Chen, ... Nature medicine 15 (5), 559-565, 2009 | 756 | 2009 |
| Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ... JAMA oncology 1 (5), 582-591, 2015 | 702 | 2015 |
| Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling J Luo, DJ Duggan, Y Chen, J Sauvageot, CM Ewing, ML Bittner, JM Trent, ... Cancer research 61 (12), 4683-4688, 2001 | 673 | 2001 |
| Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer R Hu, C Lu, EA Mostaghel, S Yegnasubramanian, M Gurel, C Tannahill, ... Cancer research 72 (14), 3457-3462, 2012 | 658 | 2012 |
| Breaking the scaling relationship via thermally stable Pt/Cu single atom alloys for catalytic dehydrogenation G Sun, ZJ Zhao, R Mu, S Zha, L Li, S Chen, K Zang, J Luo, Z Li, SC Purdy, ... Nature Communications 9 (1), 4454, 2018 | 588 | 2018 |
| Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis B Gurel, T Iwata, CM Koh, RB Jenkins, F Lan, C Van Dang, JL Hicks, ... Modern pathology 21 (9), 1156-1167, 2008 | 512 | 2008 |
| miR-21: an androgen receptor–regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth J Ribas, X Ni, M Haffner, EA Wentzel, AH Salmasi, WH Chowdhury, ... Cancer research 69 (18), 7165-7169, 2009 | 505 | 2009 |
| Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with … ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ... Journal of Clinical Oncology 35 (19), 2149-2156, 2017 | 469 | 2017 |
| Androgen receptor splice variant-7 expression emerges with castration resistance in prostate cancer A Sharp, I Coleman, W Yuan, C Sprenger, D Dolling, DN Rodrigues, ... The Journal of clinical investigation 129 (1), 192-208, 2019 | 371 | 2019 |
| Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death A Apostolou, Y Shen, Y Liang, J Luo, S Fang Experimental cell research 314 (13), 2454-2467, 2008 | 344 | 2008 |
| Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 37 (13), 1120-1129, 2019 | 332 | 2019 |
| Human prostate cancer precursors and pathobiology AM De Marzo, AK Meeker, S Zha, J Luo, M Nakayama, EA Platz, ... Urology 62 (5), 55-62, 2003 | 302 | 2003 |
| The mutational landscape of prostate cancer CE Barbieri, CH Bangma, A Bjartell, JWF Catto, Z Culig, H Grönberg, ... European urology 64 (4), 567-576, 2013 | 300 | 2013 |
| DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases MJ Aryee, W Liu, JC Engelmann, P Nuhn, M Gurel, MC Haffner, D Esopi, ... Science translational medicine 5 (169), 169ra10-169ra10, 2013 | 287 | 2013 |
| Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study MT Schweizer, ES Antonarakis, H Wang, AS Ajiboye, A Spitz, H Cao, ... Science translational medicine 7 (269), 269ra2-269ra2, 2015 | 269 | 2015 |
| A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities R Hu, WB Isaacs, J Luo The Prostate 71 (15), 1656-1667, 2011 | 247 | 2011 |
| Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects R Ferraldeschi, J Welti, J Luo, G Attard, JS De Bono Oncogene 34 (14), 1745-1757, 2015 | 219 | 2015 |
William B. IsaacsProfessor of Urology and Oncology, Brady Urological Inst, Johns Hopkins Univ, School of Medicine在 jhmi.edu 的电子邮件经过验证